Owkin uses AI to find the right treatment for every patient
We bridge shared innovation challenges between biopharma and academic researchers and close the translational gap between complex biology and new drugs.
Everything starts with patient data
Owkin has a new way of seeing the patient and their disease. We subtype patients with distinct biology to find patterns in disease mechanisms which could lead to novel targets and therapies.
Federated Data Network
Substra powers our federated data network giving us access to rich, multimodal patient data to run our internal R&D and help deliver biopharma projects. The technology platform we are developing will be a collaboration zone that connects top academic researchers and data scientists to maximize the value of their data.
Biomarkers & subgroups
We apply AI to multimodal, KOL-defined data to subtype patients and identify novel biomarkers to inform drug discovery, de-risk clinical trials and develop and deploy diagnostics in clinical practice.
Our drug discovery engines combine our expertise in AI, biology and medicine to fully understand the disease patterns and complex biological interactions defining specific patient subgroups. Our models identify and rank genes and proteins to discover novel targets, pathways, indications, drugs and combinations.
Owkin is establishing partnerships to develop these capabilities.
Our machine learning methodologies de-risk and accelerate clinical trials using patient data and innovative modalities.
Our solutions help pre-screen for biomarkers, and predict outcomes— giving healthcare providers a fuller picture of a patient’s disease. This means more patients can benefit from targeted therapies, making precision medicine more accessible to more patients at an earlier stage of their disease.
Hear from our partners
01 / 03
“Owkin’s unique methodology, which applies AI to patient data from partnerships with multiple academic medical centres, supports our ambition to leverage data in innovative ways in R&D. We are striving to advance precision medicine and to discover innovative treatment methods with the greatest benefits for patients.”
Executive Vice President, Chief Digital Officer, Sanofi
02 / 03
“Owkin combines the power of trials, labs and data science to converge towards the delivery of personalized value-based medicine. Thanks to Owkin's sophisticated computation and inference, together we have generated insights, enabling us to reason and learn, to empower our decision making.”
Chair of Urology at the Medical University of Vienna
03 / 03
“Without federated learning, most biomedical data would likely remain unused and unavailable to construct the next generation of predictive algorithms.”
Director of Caryl and Israel Englander Institute for Precision Medicine at Cornell University
Join the conversation
Join the conversation
Owkin launches open science push by open sourcing AI software Substra and releasing two open source AI innovations at NeurIPSRead the press release
Visit Owkin at booth 219 at NeurIPS (Nov. 28th - Dec. 9th, 2022) to learn about the launch of Substra and our two Federated Learning papers.Set up a meeting with us
At 5:00 pm CET on Dec. 15th, join Prof. Antoine Italiano from Gustave Roussy, Jean-Philippe Vert and Yu Fu from Owkin for a webinar to learn how deep learning can predict patient outcomes and mutations from gastrointestinal stromal tumor H&E slides.Register today
Take a closer look